House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Oncology

Muscle-invasive and metastatic bladder cancer

EAU · 2026 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

EAU’s 2026 bladder cancer guidance integrates pathological staging, patient fitness, definitive local treatment and systemic therapy. This focused summary covers selected muscle-invasive and metastatic urothelial cancer decisions, including new perioperative combinations and treatment sequencing. Choice depends on stage, prior exposure, molecular findings, toxicity risk and patient priorities; metastatic regimens must not be substituted automatically into curative treatment.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Establish stage and suitability

  • Obtain histological diagnosis and staging by TURBT with detrusor muscle in the specimen. Document tumour appearance and location; pathology should report grade, invasion depth and whether lamina propria and muscle are present. [1]
  • For confirmed muscle-invasive bladder cancer, strongly recommend CT chest, abdomen and pelvis, including urographic phases. If MRI is used for local staging, perform it before TURBT. Routine brain imaging is unnecessary without suggestive symptoms or signs. [1]
  • Discuss muscle-invasive disease in an MDT before treatment and explain cystectomy and bladder preservation to suitable patients. For older or frail patients, base selection on stage and frailty, assess comorbidity with a validated score and arrange geriatric assessment when screening identifies frailty or cognitive impairment. [1]

Match systemic treatment to the surgical setting

  • Strongly offer perioperative cisplatin/gemcitabine plus durvalumab for T2–T4a, cN0–1 M0 muscle-invasive bladder cancer when eligible for both cisplatin and immunotherapy. The formal recommendation permits GFR ≥40 mL/min; this is not the sole eligibility criterion. [1]
  • Strongly offer perioperative enfortumab vedotin plus pembrolizumab to patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy. [1]
  • Strongly offer neoadjuvant cisplatin-based combination chemotherapy for eligible T2–T4a, cN0–1 M0 disease. Do not replace it with neoadjuvant carboplatin combinations when cisplatin is unsuitable. [1]
  • After cystectomy, strongly offer adjuvant cisplatin-based combination chemotherapy for pT3/4 and/or pN+ disease when no neoadjuvant systemic therapy was given. [1]
  • Strongly offer adjuvant nivolumab for high-risk muscle-invasive urothelial cancer—≥ypT2N0 after neoadjuvant chemotherapy, or pT3/4 and/or pN+—when adjuvant cisplatin is unsuitable or declined. EAU notes FDA approval regardless of PD-L1, but EMA approval requires tumour-cell PD-L1 ≥1%. [1]

Deliver definitive treatment and continuing surveillance

  • Strongly offer radical cystectomy for T2–T4a N0M0 disease, with standard pelvic lymph-node dissection. Extended dissection does not improve survival and increases morbidity. Avoid delaying cystectomy beyond three months unless neoadjuvant chemotherapy is being given. [1]
  • Discuss urinary-diversion choices before cystectomy. Do not construct an orthotopic substitute when invasive tumour involves the urethra or urethral dissection level. Strongly offer pharmacological VTE prophylaxis from the first postoperative day for at least four weeks. [1]
  • Offer cystectomy or trimodality therapy as curative options for eligible patients. Trimodality therapy combines maximal feasible TURBT and concurrent chemoradiation; it best suits solitary unifocal cT2–T3a disease, no extensive/multifocal CIS, no or unilateral hydronephrosis and good bladder function. [1]
  • Do not use chemotherapy alone or TURBT alone as routine curative treatment for localised muscle-invasive disease. Radiotherapy alone is less effective than trimodality therapy and is reserved for patients unsuitable for cystectomy or concurrent radiosensitisation. [1]
  • Strongly perform restaging CT after neoadjuvant treatment to exclude local progression or metastatic disease before definitive local treatment. [1]
  • After cystectomy, individualise oncological and functional follow-up. The panel suggests CT every six months through year three, then annually. Monitor diversion complications including renal dysfunction, acidosis and infection; measure vitamin B12 annually after bowel diversion. [1]
  • After trimodality therapy, maintain lifelong bladder monitoring. Expert consensus uses cystoscopy every three months for two years, every six months to year five, then annually. Muscle-invasive bladder recurrence warrants prompt assessment for salvage cystectomy when feasible. [1]

Sequence therapy by fitness and previous exposure

  • For untreated metastatic urothelial cancer eligible for combination therapy, strongly offer enfortumab vedotin plus pembrolizumab. Assess organ function and treatment-specific suitability; proactively monitor skin toxicity, neuropathy, ocular effects and hyperglycaemia through an experienced MDT. [1]
  • For metastatic urothelial cancer, if enfortumab is contraindicated or unavailable, strongly offer platinum/gemcitabine followed by avelumab maintenance when chemotherapy produces at least stable disease. Choose cisplatin or carboplatin according to fitness; they are not interchangeable in cisplatin-fit patients. [1]
  • For metastatic urothelial cancer, if enfortumab is contraindicated or unavailable and the patient is cisplatin-eligible, cisplatin/gemcitabine plus nivolumab is a strong first-line alternative. If both enfortumab and checkpoint-inhibitor therapy are contraindicated, use platinum/gemcitabine alone. [1]
  • For metastatic disease ineligible for combination therapy, EAU weakly recommends single-agent pembrolizumab or atezolizumab when PD-L1 is high. EMA-linked thresholds differ: pembrolizumab CPS ≥10 and atezolizumab ≥5% tumour-infiltrating immune cells, using the specified drug-associated assays. [1]
  • For metastatic urothelial cancer, after prior enfortumab plus a checkpoint inhibitor, EAU weakly recommends platinum/gemcitabine; strongly offer erdafitinib for actionable FGFR alterations. Select erdafitinib using susceptible FGFR3 alterations and review previous toxicity when planning subsequent chemotherapy. [1]
  • For metastatic urothelial cancer, after platinum-based therapy with or without a checkpoint inhibitor, strongly offer enfortumab; offer erdafitinib when actionable FGFR alterations and prior checkpoint-inhibitor exposure are present. If no checkpoint inhibitor was previously given, strongly offer pembrolizumab. [1]
  • For metastatic urothelial cancer, after enfortumab, checkpoint inhibition and platinum, EAU weakly recommends trastuzumab deruxtecan for HER2 IHC 3+ disease and consideration for IHC 2+. This later-line recommendation requires biomarker selection; it is not a first-line substitute. [1]
  • Offer clinical trials for further metastatic treatment. Consider best supportive care alone when the patient is not a candidate for additional cancer-specific systemic therapy; uncertain sequencing should not be presented as an established universal regimen. [1]

Address the impact of treatment

  • Assess quality of life before and after treatment with validated questionnaires. Discuss diversion in relation to preferences, comorbidities and coping abilities. Watch for mental-health difficulties after surgery and facilitate specialist support; peer support complements professional care. [1]

Limitations and use

  • This selected pathway summary does not establish complete drug doses, cycles, toxicity-management protocols, radiotherapy planning, urinary-diversion eligibility or non-urothelial histology treatment. Non-muscle-invasive bladder cancer has separate guidance.
  • Drug approvals, assay criteria and access vary by jurisdiction. FDA/EMA distinctions described here do not establish Indian approval or reimbursement. Eligibility for cisplatin and immunotherapy requires full assessment, not a renal threshold alone.
  • For perioperative chemoimmunotherapy, the formal recommendation table specifies cN0–1 and GFR ≥40 mL/min; introductory highlights differ. The formal table is followed. Metastatic platinum-fitness tables and flowcharts use varying renal cutoffs; this summary does not create a single universal renal-eligibility rule.
  • Post-cystectomy surveillance intervals are a practice-based framework, not a prospectively proven survival-improving schedule. Follow-up requires individual risk and functional assessment. Adjuvant radiotherapy, oligometastatic local treatment and detailed recurrence-site pathways are not fully covered.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Muscle-invasive and metastatic bladder cancer

    Selected recommendation material consulted

Clinical guideline

Publication details

Issuing organisation
EAU
Resource type
Clinical guideline · House clinical summary
Source setting
Europe

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Establish stage and suitability
  • Match systemic treatment to the surgical setting
  • Deliver definitive treatment and continuing surveillance
  • Sequence therapy by fitness and previous exposure
  • Address the impact of treatment
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House